ELCC 2014: Sponsors
Amgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics.
Stand no. 1111
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. Our BMS Foundation philanthropic programs seek to reduce health disparities and improve health outcomes, giving new hope to some of the world’s most vulnerable people.
As a BioPharma leader, we believe what sets us apart is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases.
Stand no. 1221
For more than four decades,
Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches that accelerate the pace and progress of cancer care. We also understand cancer care is complex and we’re working to provide support services that are meaningful for you and your patients.
Stand no. 1211
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.
Stand no. 1021
Headquartered in Basel, Switzerland,
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Stand no. 1121
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. The family-owned company is committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
Stand no. 1130 and 1229
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide”.
Stand Number: 1330
MSD Merck Sharp & Dohme AG
MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
Stand no. 1131
Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help physicians meet patient needs, with one of the broadest and most comprehensive oncology pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways. Visit our website for more information about how we are transforming the treatment of cancer and other diseases.
Stand no. 1031
Clovis Oncology is committed to realising the promise of personalised medicines for cancer. Clovis seeks to develop targeted therapies in combination with companion diagnostics to ensure the right drug gets to the right patient. Clovis Oncology currently has three clinical product candidates. The lead programme, CO-1686, is an oral, selective epidermal growth factor receptor (EGFR) inhibitor which targets both the activating mutations of EGFR as well as the primary resistance mutation, T790M. CO-1686 is the subject of a broad, pivotal development programme for the treatment of EGFR mutant NSCLC.
Stand number: 1231
Wisepress are Europe’s principal conference bookseller. We exhibit the leading books, sample journals and digital content relevant to this meeting. Books may be purchased at the booth, and we offer a postal service. Visit our online bookshop for special offers and follow us on Twitter for the latest news @WisepressBooks.
Stand no. 1030